APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors

Clinical trial NCT05701306 · RECRUITING

Trial details

NCT number: NCT05701306
Sponsor: Ascentage Pharma Group Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Neuroblastoma Solid Tumor

Start date: 2023-02-28
Primary completion: 2027-06-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.